Pages that link to "Q68663014"
Jump to navigation
Jump to search
The following pages link to A depression rating scale for schizophrenics (Q68663014):
Displaying 50 items.
- Yoga versus standard care for schizophrenia (Q24186431) (← links)
- Antiglucocorticoid and related treatments for psychosis (Q24186594) (← links)
- Haloperidol dose for the acute phase of schizophrenia (Q24200200) (← links)
- Haloperidol versus placebo for schizophrenia (Q24202457) (← links)
- Early intervention for psychosis (Q24236296) (← links)
- Lamotrigine for schizophrenia (Q24243946) (← links)
- Assessment of depression in medical patients: a systematic review of the utility of the Beck Depression Inventory-II (Q27006705) (← links)
- Investigating the feasibility and acceptability of a cognitive behavioural suicide prevention therapy for people in acute psychiatric wards (the 'INSITE' trial): study protocol for a randomised controlled trial (Q27334611) (← links)
- Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia (Q28240120) (← links)
- Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study. (Q28277784) (← links)
- Increased prolactin levels are associated with impaired processing speed in subjects with early psychosis (Q28540093) (← links)
- Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial (Q28552053) (← links)
- Converting positive and negative symptom scores between PANSS and SAPS/SANS (Q28660667) (← links)
- Criterion and construct validity of the CogState Schizophrenia Battery in Japanese patients with schizophrenia (Q28744227) (← links)
- Treating Depressive Symptoms in Psychosis: A Network Meta-Analysis on the Effects of Non-Verbal Therapies (Q30380499) (← links)
- Preliminary evidence for reduced auditory lateral suppression in schizophrenia (Q30389978) (← links)
- Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia (Q30436445) (← links)
- A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia (Q30498769) (← links)
- The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation (Q30547123) (← links)
- Altered resting-state EEG source functional connectivity in schizophrenia: the effect of illness duration (Q30647676) (← links)
- The Function Biomedical Informatics Research Network Data Repository (Q30679446) (← links)
- Neuropsychology, social cognition and global functioning among bipolar, schizophrenic patients and healthy controls: preliminary data (Q30681799) (← links)
- Evaluation of different approaches for confounding in nonrandomised observational data: a case-study of antipsychotics treatment (Q30792325) (← links)
- Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data (Q30882594) (← links)
- The feasibility and validity of ambulatory self-report of psychotic symptoms using a smartphone software application. (Q33439138) (← links)
- Using mobile technology to deliver a cognitive behaviour therapy-informed intervention in early psychosis (Actissist): study protocol for a randomised controlled trial (Q33445067) (← links)
- Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone (Q33545458) (← links)
- Bipolar disorder risk gene FOXO6 modulates negative symptoms in schizophrenia: a neuroimaging genetics study (Q33599296) (← links)
- A randomized controlled trial of cognitive remediation in schizophrenia. (Q33707653) (← links)
- Social functioning in urban, predominantly African American, socially disadvantaged patients with first-episode nonaffective psychosis (Q33846913) (← links)
- Psychosocial factors contributing to suicidal ideation in hospitalized schizophrenia patients in Korea (Q33935248) (← links)
- Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial (Q34007868) (← links)
- Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study (Q34073723) (← links)
- Toward a model of cognitive insight in first-episode psychosis: verbal memory and hippocampal structure (Q34092662) (← links)
- Acquired self-control of insula cortex modulates emotion recognition and brain network connectivity in schizophrenia (Q34226691) (← links)
- Initial development and preliminary validation of a new negative symptom measure: The Clinical Assessment Interview for Negative Symptoms (CAINS) (Q34311294) (← links)
- Antipsychotic treatment for children and adolescents with schizophrenia spectrum disorders: protocol for a network meta-analysis of randomised trials. (Q34327978) (← links)
- Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases (Q34350145) (← links)
- A prospective study of health care resource utilisation and selected costs of schizophrenia in France (Q34386873) (← links)
- Fluvoxamine as an adjunctive agent in schizophrenia (Q34405313) (← links)
- Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. (Q34424470) (← links)
- Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials (Q34432085) (← links)
- Understanding the Outcomes Measures used in Huntington Disease Pharmacological Trials: A Systematic Review (Q34443430) (← links)
- Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia (Q34481351) (← links)
- NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study (Q34492934) (← links)
- Reviewing the Effectiveness of Music Interventions in Treating Depression (Q34558890) (← links)
- A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia (Q34579324) (← links)
- High-frequency prefrontal repetitive transcranial magnetic stimulation for the negative symptoms of schizophrenia: a case series (Q34590128) (← links)
- Death by suicide long after electroconvulsive therapy. Is the sense of coherence test of Antonovsky a predictor of mortality from depression? (Q34618808) (← links)
- Depressive symptoms in first episode psychosis: a one-year follow-up study (Q34656685) (← links)